Key clinical point: Dupilumab improved clinical scores in a real-world population of adolescents with moderate-to-severe atopic dermatitis (AD) and had a tolerable safety profile.
Major finding: After 16 weeks, the mean Eczema Area and Severity Index (EASI) score and Children Dermatology Life Quality Index and Numeric Rating Scale sleep loss scores reduced significantly by 79.8%, 72.9%, and 75.8%, respectively (all P < .01), with a higher proportion of patients with diffuse eczema vs. other clinical phenotypes reporting ≥90% and 100% improvement in EASI scores ( P < .05). Adverse events (AE) were reported by 20.1% of adolescents, but none discontinued dupilumab because of AE.
Study details: This prospective study included 139 adolescents aged ≥12 to <18 years with moderate-to-severe AD who received dupilumab for 16 weeks.
Disclosures: This study did not receive any funding. Some authors declared serving as principal investigators, advisory board members, speakers, or consultants, or receiving personal fees, consulting fees, or payments or honoraria from several sources.
Source: Stingeni L et al. Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience. J Eur Acad Dermatol Venereol. 2022 (Apr 12). Doi: 10.1111/jdv.18141